Daré Bioscience ((DARE)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Daré Bioscience is currently conducting a pivotal clinical study titled ‘A Single Arm, Open-Label Pivotal Contraceptive Efficacy Study of Ovaprene.’ The study aims to evaluate the contraceptive effectiveness, safety, and acceptability of Ovaprene, a non-hormonal intravaginal ring. This research is significant as it explores a novel contraceptive option that could expand choices for women seeking non-hormonal methods.
The intervention being tested is Ovaprene, an experimental device designed as a non-hormonal intravaginal ring. Its purpose is to provide effective contraception without the use of hormones, potentially appealing to those who prefer or require non-hormonal options.
The study is designed as an interventional, single-group assignment with no masking, focusing on prevention. This open-label approach allows all participants to receive the Ovaprene device, facilitating direct observation of its contraceptive efficacy and safety.
The study began on November 7, 2023, with an estimated completion date in September 2025. The primary completion date is yet to be determined. These timelines are crucial for investors tracking the progress and potential market entry of Ovaprene.
This study update could influence Daré Bioscience’s stock performance positively, as successful results may enhance investor confidence and position the company as a leader in innovative contraceptive solutions. The involvement of the Eunice Kennedy Shriver National Institute of Child Health and Human Development underscores the study’s importance and credibility within the industry.
The study is ongoing, with further details available on the ClinicalTrials portal.